Matthew Carabasi

Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation

Esperanza B. Papadopoulos, Marc Ladanyi, David Emanuel et al. · New England Journal of Medicine · 1994 · 1.1K citations · Full text

Medicine, Hematology, Immunology +12

T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease

Esperanza B. Papadopoulos, Matthew Carabasi, Hugo Castro‐Malaspina et al. · Blood · 1998 · 219 citations · Full text

Medicine, Hematology, Oncology +14

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

John Horan, Brent R. Logan, Afiba Manza‐A. Agovi et al. · Journal of Clinical Oncology · 2011 · 200 citations · Full text

Medicine, Hematology, Immunology +17

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Nancy L. Bartlett, Anas Younes, Matthew Carabasi et al. · Blood · 2007 · 196 citations · Full text

Medicine, Hematology, Oncology +8

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Stephanie J. Lee, Manisha Kukreja, Tao Wang et al. · Blood · 2008 · 134 citations · Full text

Medicine, Hematology, Pharmacotherapy +11